Is ASCO Sending Mixed Messages On Cancer Drug Value?

Endorsing a framework that incorporates cost and value implies that all relevant stakeholders, not just oncologists and their patients, would be included in the design of framework criteria that are intended to inform decisions on which drugs to develop, market, prescribe, and reimburse.

Read the full post on Forbes - Pharma & Healthcare